NexoBrid (concentrate of proteolytic enzymes enriched in bromelain)
- Region
- 🇪🇺 EU
- Active substance
- concentrate of proteolytic enzymes enriched in bromelain
- Company
- MediWound Germany GmbH
- Status
- Authorised
- Therapeutic area
- Debridement
- CHMP opinion
- Thu 20 Sep 2012
- EU approval
- Tue 18 Dec 2012
- Application
- EMEA/H/C/002246
- ATC
- D03BA03
- Official record
- www.ema.europa.eu
Indication
NexoBrid is indicated in all age groups for removal of eschar in patients with deep partial- and full-thickness thermal burns.
Regulatory milestones
No milestones recorded in the last year.
Follow NexoBrid
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.